ABOS
Price
$2.48
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
54 days until earnings call
INZY
Price
$5.83
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
48 days until earnings call
Ad is loading...

ABOS vs INZY

Header iconABOS vs INZY Comparison
Open Charts ABOS vs INZYBanner chart's image
Acumen Pharmaceuticals
Price$2.48
Change-$0.00 (-0.00%)
Volume$135.26K
CapitalizationN/A
Inozyme Pharma
Price$5.83
Change-$0.00 (-0.00%)
Volume$195.96K
CapitalizationN/A
View a ticker or compare two or three
ABOS vs INZY Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABOS vs. INZY commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongSell and INZY is a Buy.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (ABOS: $2.48 vs. INZY: $5.83)
Brand notoriety: ABOS and INZY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 52% vs. INZY: 71%
Market capitalization -- ABOS: $149M vs. INZY: $391.19M
ABOS [@Biotechnology] is valued at $149M. INZY’s [@Biotechnology] market capitalization is $391.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $609.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileINZY’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • INZY’s FA Score: 0 green, 5 red.
According to our system of comparison, INZY is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 6 TA indicator(s) are bullish while INZY’s TA Score has 6 bullish TA indicator(s).

  • ABOS’s TA Score: 6 bullish, 4 bearish.
  • INZY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ABOS and INZY are a good buy in the short-term.

Price Growth

ABOS (@Biotechnology) experienced а -1.20% price change this week, while INZY (@Biotechnology) price change was +10.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.17%. For the same industry, the average monthly price growth was +1.67%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 11, 2024.

INZY is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Biotechnology (+1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INZY($391M) has a higher market cap than ABOS($149M). INZY YTD gains are higher at: 36.854 vs. ABOS (-35.417). ABOS has higher annual earnings (EBITDA): -62.11M vs. INZY (-82.82M). ABOS has more cash in the bank: 260M vs. INZY (145M). ABOS has less debt than INZY: ABOS (28.2M) vs INZY (46.7M). ABOS (0) and INZY (0) have equivalent revenues.
ABOSINZYABOS / INZY
Capitalization149M391M38%
EBITDA-62.11M-82.82M75%
Gain YTD-35.41736.854-96%
P/E RatioN/AN/A-
Revenue00-
Total Cash260M145M179%
Total Debt28.2M46.7M60%
TECHNICAL ANALYSIS
Technical Analysis
ABOSINZY
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSEQX59.110.42
+0.72%
JPMorgan Small Cap Equity R4
JCVCX34.650.12
+0.35%
JHancock Classic Value C
CMRGX10.000.02
+0.20%
Calamos Merger Arbitrage I
NCEGX22.32N/A
N/A
The North Country Large Cap Equity Fund
LIDAX8.36-0.05
-0.59%
Lord Abbett International Value A

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with NTLA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-2.36%
NTLA - ABOS
50%
Loosely correlated
+4.83%
ABCL - ABOS
49%
Loosely correlated
+1.87%
SEER - ABOS
45%
Loosely correlated
+2.38%
INZY - ABOS
44%
Loosely correlated
-2.67%
BEAM - ABOS
44%
Loosely correlated
-0.16%
More

INZY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
-2.67%
BEAM - INZY
58%
Loosely correlated
-0.16%
NTLA - INZY
54%
Loosely correlated
+4.83%
DNLI - INZY
50%
Loosely correlated
+1.15%
PLRX - INZY
49%
Loosely correlated
+6.15%
SEER - INZY
49%
Loosely correlated
+2.38%
More